Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 1366

1.

Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.

Duchnowska R, Loibl S, Jassem J.

Cancer Treat Rev. 2018 Jun;67:71-77. doi: 10.1016/j.ctrv.2018.05.004. Epub 2018 May 9. Review.

PMID:
29772459
2.

Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart M.

Cancer Treat Rev. 2018 Jun;67:10-20. doi: 10.1016/j.ctrv.2018.04.016. Epub 2018 May 2. Review.

PMID:
29751334
3.

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.

Verma S, Goyal S, Kumari A, Singh A, Jamal S, Grover A.

PLoS One. 2018 Feb 1;13(2):e0190942. doi: 10.1371/journal.pone.0190942. eCollection 2018.

4.

Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.

Albiol-Chiva J, Esteve-Romero J, Peris-Vicente J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Feb 1;1074-1075:61-69. doi: 10.1016/j.jchromb.2017.12.034. Epub 2018 Jan 2.

PMID:
29331859
5.

A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer.

Chen TW, Yeh DC, Chao TY, Lin CH, Chow LW, Chang DY, Hsieh YY, Huang SM, Cheng AL, Lu YS, Consortium TBC.

Jpn J Clin Oncol. 2018 Mar 1;48(3):242-247. doi: 10.1093/jjco/hyx188.

PMID:
29315394
6.

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.

Stein S, Zhao R, Haeno H, Vivanco I, Michor F.

PLoS Comput Biol. 2018 Jan 2;14(1):e1005924. doi: 10.1371/journal.pcbi.1005924. eCollection 2018 Jan.

7.

Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.

Madden R, Kosari S, Peterson GM, Bagheri N, Thomas J.

Int J Clin Pharmacol Ther. 2018 Feb;56(2):72-80. doi: 10.5414/CP203123. Review.

PMID:
29231164
8.

[Mechanism underlying inhibition of proliferation and promotion of apoptosis by lapatinib in HL60 cells].

Liu L, Liu B, Zhao Y, Chen M, Yao S, Li L, Xiao C, Shan Z, Xu T, Gan L, Zhong L.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Oct;33(10):1341-1347. Chinese.

PMID:
29169418
9.

The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer.

Nakashoji A, Hayashida T, Yokoe T, Maeda H, Toyota T, Kikuchi M, Watanuki R, Nagayama A, Seki T, Takahashi M, Abe T, Kitagawa Y.

Cancer Treat Rev. 2018 Jan;62:9-17. doi: 10.1016/j.ctrv.2017.10.009. Epub 2017 Oct 31. Review.

PMID:
29127857
10.

The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.

Koch KM, Dees EC, Coker SA, Reddy NJ, Gainer SD, Arya N, Beelen AP, Lewis LD.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1141-1146. doi: 10.1007/s00280-017-3470-y. Epub 2017 Nov 2.

PMID:
29098381
11.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

PMID:
29059433
12.

Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.

Shu T, Li Y, Wu X, Li B, Liu Z.

Cancer Lett. 2017 Dec 28;411:65-73. doi: 10.1016/j.canlet.2017.09.048. Epub 2017 Oct 6.

PMID:
28989055
13.

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.

Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, Charafe-Jauffret E, Hervieu A, Extra JM, Viens P, Lokiec F, Boher JM, Gonçalves A.

Eur J Cancer. 2017 Nov;86:28-36. doi: 10.1016/j.ejca.2017.08.025. Epub 2017 Sep 23.

PMID:
28950146
14.

Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells.

Ma S, Dielschneider RF, Henson ES, Xiao W, Choquette TR, Blankstein AR, Chen Y, Gibson SB.

PLoS One. 2017 Aug 21;12(8):e0182921. doi: 10.1371/journal.pone.0182921. eCollection 2017.

15.

The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.

Petrelli F, Ghidini M, Lonati V, Tomasello G, Borgonovo K, Ghilardi M, Cabiddu M, Barni S.

Eur J Cancer. 2017 Oct;84:141-148. doi: 10.1016/j.ejca.2017.07.024. Epub 2017 Aug 12. Review.

PMID:
28810186
16.

Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.

Singla H, Ludhiadch A, Kaur RP, Chander H, Kumar V, Munshi A.

Eur J Med Chem. 2017 Dec 15;142:316-327. doi: 10.1016/j.ejmech.2017.07.075. Epub 2017 Aug 1. Review.

PMID:
28800870
17.

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ.

Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049. doi: 10.1126/scitranslmed.aam7049.

PMID:
28768804
18.

Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.

Srivastava S, Mohibi S, Mirza S, Band H, Band V.

Cell Cycle. 2017 Aug 18;16(16):1515-1525. doi: 10.1080/15384101.2017.1339846. Epub 2017 Jul 31.

19.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

20.

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO.

JAMA Oncol. 2017 Nov 9;3(11):e172085. doi: 10.1001/jamaoncol.2017.2085. Epub 2017 Nov 9.

PMID:
28750133

Supplemental Content

Support Center